ONE CYPASS
®
MICROSTENT IS ALL IT TAKES TO CONNECT
TO SAFE, CONSISTENT, LONGTERM IOP CONTROL
and done
© 2018 Novartis 2/18 US-CYP-18-E-0312
FOR AN EXPERIENCE LIKE NO OTHER, CONNECT WITH AN ALCON REPRESENTATIVE TODAY.
IN THE COMPASS STUDY AT TWO YEARS
1,2
:
• 72.5% of patients achieved a ≥20% reduction in IOP (n=374)
• 93% of responders were medication free*
• Safety profi le similar to cataract surgery alone
References: 1. CyPass
®
Micro-Stent Instructions for Use. 2. Vold S, Ahmed IIK, Craven ER, et al. Two-year COMPASS trial results: supraciliary microstenting with
phacoemulsifi cation in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103-2112.
FOR THE REDUCTION OF IOP IN MILD TO MODERATE PRIMARY
OPENANGLE GLAUCOMA AT THE TIME OF CATARACT SURGERY
*Those patients who attained an unmedicated mean diurnal IOP reduction of 20% or more as compared to baseline in the absence of IOP-a™ ecting surgery during the study.
and done
NOW NOW
AVAILABLE
